Cabozantinib significantly improved overall survival as compared with everolimus
US biotech firm Exelixis (Nasdaq: EXEL) has announced positive overall survival (OS) results from METEOR, the Phase III pivotal trial comparing cabozantinib to everolimus in 658 patients with advanced renal cell carcinoma (RCC) who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI).
In early trading on Monday, the stock rose 3% at $4.75, although it ended just 1.10% higher at $4.60 in after-hours trading. That followed a 10.5% rise to $4.62 on Friday, with a consensus analyst price target of $11.00 and a 52-week trading range of $1.80 to $6.81, when the company announced that the US Food and Drug Administration had accepted its rolling New Drug Application (NDA) application for cabozantinib for review, as well as the European Medicines Agency’s acceptance of its application to market cabozantinib as a treatment for kidney cancer for priority assessment.
Study details
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze